New pill targets leukemia in early human trial

NCT ID NCT05918692

Ongoing Disease control Sponsor: Biomea Fusion Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental pill called BMF-500 in 35 adults with acute leukemia, especially those with a specific genetic mutation (FLT3). The main goals are to check the drug's safety, find the right dose, and see if it can help control the disease. Participants must have leukemia that has come back or not improved after prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMF-500 (an oral FLT3 inhibitor)
What this could lead to: If successful, this could lead to a new targeted treatment option for patients with acute leukemia that has returned or not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, so it is primarily testing safety and dosing. The drug may not prove effective or could have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

City of Hope National Medical Center

Duarte, California, 91010, United States
Colorado Blood Cancer Institute

Denver, Colorado, 80218, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55902, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Texas Oncology-PA USOR

Dallas, Texas, 75251, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Kentucky - Markey Cancer Center

Lexington, Kentucky, 40536, United States
Virginia Cancer Specialists

Gainesville, Virginia, 20155, United States
Winship Cancer Institute, Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.